Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Oregon Health and Science University
300 participants
Sep 24, 2025
OBSERVATIONAL
Conditions
Summary
The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes, and patient reported quality of life after 6 months of use of either of two commonly used hormonal treatments for menstrual suppression - levonorgestrel intrauterine device (LNG-IUD) and norethindrone acetate (NETA). Under this application the study will compare the two treatments and compare outcomes after LNG-IUD treatment results to a control group without a bleeding disorder, with the goal of determining the benefits and expected outcomes of these treatment options for this population.
Eligibility
Inclusion Criteria6
- Post-menarcheal
- Ages 10-24
- Decision to initiate a trial of progestin therapy with either LNG-IUD or NETA
- Able to provide assent and written informed consent by one parent (ages \<18) or written informed consent (age 18+)
- Must meet trial criteria for heavy menstrual bleeding
- Must meet trial criteria for a bleeding disorder or have minimum workup to rule out bleeding disorder
Exclusion Criteria1
- Pregnant or seeking pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
52 mg levonorgestrel intrauterine system
norethindrone acetate 5 mg daily
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05916469